Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Natural killer cell therapy - Shenzhen Hank Bioengineering Institute

Next Previous
X
Search
Drug Profile

Natural killer cell therapy - Shenzhen Hank Bioengineering Institute

Alternative Names: HANK cell - Shenzhen Hank Bioengineering Institute; High-activity natural killer cells - Shenzhen Hank Bioengineering Institute; Natural killer immunotherapy - Shenzhen Hank Bioengineering Institute

Latest Information Update: 23 Feb 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator HANK Bioengineering
  • Developer Fuda Cancer Hospital; HANK Bioengineering
  • Class Antineoplastics; Cell therapies; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported B-cell lymphoma; Breast cancer; Cervical cancer; Colorectal cancer; Laryngeal cancer; Liver cancer; Malignant melanoma; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Pharyngeal neoplasms; Renal cancer; Soft tissue sarcoma; Solid tumours; Tongue cancer

Most Recent Events

  • 23 Feb 2022 No development reported - Phase-I/II for B-cell lymphoma (Combination therapy, Recurrent, Second-line therapy or greater) in China (IV)
  • 23 Feb 2022 No development reported - Phase-I/II for Breast cancer (Combination therapy, Recurrent, Second-line therapy or greater) in China (IV)
  • 23 Feb 2022 No development reported - Phase-I/II for Breast cancer (Late-stage disease, Monotherapy, Recurrent, Second-line therapy or greater, Adjuvant therapy) in China (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top